# Immunocore Holdings plc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Immunocore Holdings plc). ## Overview Immunocore Holdings plc is a commercial-stage biotechnology company built around its proprietary ImmTAX platform, which engineers TCR-based medicines to redirect the immune system against cancer, infectious diseases, and autoimmune disease. Its first approved product, KIMMTRAK, is marketed for unresectable or metastatic uveal melanoma, while the rest of the pipeline remains in clinical and preclinical development. ## Products & services • KIMMTRAK (tebentafusp-tebn) for unresectable/metastatic uveal melanoma • ImmTAX platform for TCR-based immunomodulating medicines • Oncology pipeline, including brenetafusp and PRAME-directed programs • Infectious disease programs, including HBV candidate IMC-I109V • Autoimmune disease discovery and preclinical programs - **Commercial oncology product** (100%) — Approved therapy sold to treat unresectable or metastatic uveal melanoma. - **Clinical-stage oncology pipeline** (0%) — Investigational TCR-based cancer programs aimed at expanding beyond KIMMTRAK. - **Infectious disease pipeline** (0%) — Clinical programs targeting chronic viral disease, including hepatitis B. - **Autoimmune discovery pipeline** (0%) — Preclinical programs designed to extend the platform into autoimmune disease. - KIMMTRAK commercial therapy for unresectable or metastatic uveal melanoma - ImmTAX platform for off-the-shelf TCR-based immunotherapies - Oncology pipeline including brenetafusp and PRAME-targeted assets - HBV and HBV-positive HCC clinical programs such as IMC-I109V - Autoimmune and earlier-stage discovery programs - Outsourced manufacturing and commercialization support for KIMMTRAK ## Customers Immunocore sells primarily to distributors, hospitals, and healthcare providers that administer KIMMTRAK to eligible patients with uveal melanoma. The end demand is driven by oncologists and treatment centers in major markets such as the United States and Europe, where reimbursement and launch execution determine uptake. For its pipeline programs, the company’s future customers would be patients, payers, and healthcare systems if and when additional products are approved. - **U.S. oncology treatment centers** (primary) — Hospitals and specialty clinics in the United States that buy KIMMTRAK for eligible mUM patients and drive the largest revenue base. - **European distributors and providers** (primary) — Regional distributors and healthcare providers in Europe that purchase and dispense KIMMTRAK under local reimbursement systems. - **International commercial partners** (secondary) — Partners such as Medison and Er-Kim that commercialize KIMMTRAK in selected territories outside core markets. - **Clinical trial investigators and sites** (secondary) — Research centers enrolling patients in PRISM-MEL-301 and HBV studies to advance the pipeline toward approval. - Oncology hospitals and infusion centers treating uveal melanoma patients - Specialty distributors and healthcare providers purchasing KIMMTRAK - Payers and reimbursement systems that influence access and uptake - Clinical trial sites enrolling patients in oncology and HBV studies - Future customers for pipeline assets if regulatory approvals are obtained ## Geography The company is headquartered in the United Kingdom, with principal offices in Abingdon and U.S. offices in Pennsylvania and Maryland. Commercial revenue is concentrated in the United States and Europe, while manufacturing and logistics are outsourced across Denmark, Germany, and the Netherlands. This geography matters because the business depends on cross-border clinical development, regulatory approvals, reimbursement negotiations, and third-party supply chains. - **United States** (64%) — Based on 2025 revenue from sale of therapies, net. - **Europe** (33%) — Based on 2025 revenue from sale of therapies, net. - **International** (3%) — Based on 2025 revenue from sale of therapies, net. - Headquartered in the United Kingdom with U.S. operating offices - Revenue is concentrated in the United States and Europe - KIMMTRAK is launched in 30 countries and approved in 39 countries - Manufacturing is outsourced to CMOs in Denmark and Germany - Global packaging, labeling, and distribution run through the Netherlands - Partner-led expansion covers Canada, Australia, MENA, and CIS regions ## Strategy Immunocore is focused on expanding KIMMTRAK adoption in existing markets while adding new country launches through partners and direct commercialization. At the same time, it is advancing a broader pipeline in oncology, HBV, and autoimmune disease to reduce dependence on a single product and create a longer-term growth base. - **Expand KIMMTRAK commercialization** (short-term) — KIMMTRAK is the only revenue-generating asset and funds the broader platform. - **Advance late-stage oncology development** (medium-term) — New oncology approvals would broaden the addressable market beyond uveal melanoma. - **Build a multi-therapeutic pipeline** (long-term) — Diversification reduces single-product dependence and improves long-term optionality. - Grow KIMMTRAK adoption in the U.S. and Europe - Launch KIMMTRAK in additional countries through 2026 - Use partners to extend reach in non-core territories - Advance PRISM-MEL-301 and other oncology trials - Develop HBV and autoimmune programs to diversify the pipeline - Rely on outsourced manufacturing to scale without owning plants ## Risks The company remains highly dependent on KIMMTRAK, so any slowdown in uptake, reimbursement, or supply would have an outsized effect on results. It also faces the usual biotechnology risks: clinical trial failure, regulatory delays, pricing pressure, and the need for additional capital before the pipeline can generate meaningful revenue. Because manufacturing and clinical operations are international and outsourced, supply-chain, compliance, and geopolitical risks are material. - **Single-product revenue concentration** [high] — KIMMTRAK is the only marketed product and funds most of the business. - **Clinical development failure** [high] — Pipeline assets may not show sufficient efficacy or safety to reach approval. - **Manufacturing and supply disruption** [high] — Production is outsourced to third-party CMOs and depends on compliant scale-up. - **International regulatory and geopolitical exposure** [medium] — Operations, suppliers, and trials span multiple jurisdictions with changing rules. - **Capital needs and dilution** [high] — The company may need external funding before pipeline assets become commercial. - Heavy dependence on one commercial product, KIMMTRAK - Clinical trial and regulatory risk across multiple pipeline programs - Reimbursement and pricing negotiations can delay or reduce revenue - Outsourced manufacturing creates supply and quality-control exposure - International operations add geopolitical, legal, and trade risks - Need for additional capital if pipeline development takes longer than expected ## Accounting Revenue is recognized at a point in time when KIMMTRAK control transfers, usually on delivery or when consignment stock is taken out of inventory, which makes sales deductions and timing estimates important. The largest judgment is the estimate of rebates, chargebacks, returns, and pricing negotiations, especially in markets such as France and Germany, where reserve changes can move reported revenue materially. Because the company is still loss-making, valuation allowances on tax assets, clinical accruals, and other estimates also matter for comparability. - **Revenue deductions reserve estimation** — A 20% change in estimated rebate/chargeback rates moved quarterly revenue by about $1.7 million. - **Consignment and delivery timing** — Can shift revenue between quarters depending on distributor inventory movements. - **Pricing negotiations in Europe** — Can create one-time changes in reported revenue and margins. - **Tax loss carryforwards and valuation allowance** — Deferred tax assets may remain partially or fully reserved. - Point-in-time revenue recognition for KIMMTRAK sales - Estimated rebates, chargebacks, and product returns reduce net revenue - Consignment arrangements affect when revenue is recorded - Pricing negotiations in Europe can change accrued deductions - Loss carryforwards and valuation allowances affect tax accounting - Clinical trial and manufacturing accruals depend on judgment --- *Last updated: 2026-04-28T20:17:03.439591+00:00*